# Filing Detail

Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001477932-26-003587
Filing Date
2026-06-02
Accepted
2026-06-02 16:21:40
Documents
8
Period of Report
2026-07-17

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEF 14A | vnrx_def14a.htm | DEF 14A | 798758
2 |  | vnrx_def14aimg100.jpg | GRAPHIC | 27217
3 |  | vnrx_def14aimg101.jpg | GRAPHIC | 151277
4 |  | vnrx_def14aimg102.jpg | GRAPHIC | 199994
5 |  | vnrx_def14aimg103.jpg | GRAPHIC | 140932
6 |  | vnrx_def14aimg104.jpg | GRAPHIC | 108472
7 |  | vnrx_def14aimg98.jpg | GRAPHIC | 23721
8 |  | vnrx_def14aimg99.jpg | GRAPHIC | 31393
| Complete submission text file | 0001477932-26-003587.txt |  | 1741380

Mailing Address 1489 WEST WARM SPRINGS ROAD SUITE 110 HENDERSON NV 89014
Business Address 1489 WEST WARM SPRINGS ROAD SUITE 110 HENDERSON NV 89014 1 (512) 774-8930
VOLITIONRX LTD (Filer) CIK: 0000093314 (see all company filings)

EIN.: 911949078 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-36833 | Film No.: 261056361
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)